The increasing prevalence of degenerative disc disease (DDD) among the elderly population and the innovations in imaging technology & surgical tools are projected to drive the global degenerative disc disease treatment market's growth during the forecast period. The North America region is predicted to witness prominent growth by 2032.

PORTLAND, Ore., May 23, 2024 /PRNewswire/ -- Allied Market Research has recently published a report, titled, "Degenerative Disc Disease Treatment Market Size, Share, Competitive Landscape and Trend Analysis Report by Drugs, By Treatment Type, By End Use, By Route of Administration : Global Opportunity Analysis and Industry Forecast, 2023-2032." According to the report, the global degenerative disc disease treatment market generated $28 billion in 2022, and is anticipated to generate $46.2 billion by 2032, rising at a CAGR of 5.5% from 2023 to 2032.

Request Sample of the Report on Degenerative Disc Disease Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/A269439 

Prime Determinants of Growth

The increasing prevalence of degenerative disc disease (DDD) among the aging population, growing awareness about spine health and available treatment options, and the innovations in imaging technology & surgical tools are the factors expected to drive the growth of the global degenerative disc disease treatment market in the forecast period from 2023 to 2032. However, the increasing availability of various alternative treatment and pain management methods for degenerative disc disease may restrict market growth in the coming future. Contrarily, technological innovations in medical technology, such as robotics, 3D printing, and advanced imaging techniques is expected to offer remunerative opportunities for the degenerative disc disease treatment market expansion during the forecast period.

Report Coverage & Details:

Have a Question? Connect to our Analyst- https://www.alliedmarketresearch.com/connect-to-analyst/A269439 

Drugs: NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Sub-segment to be the Most Dominant by 2032

The NSAIDs (non-steroid anti-inflammatory drugs) sub-segment accounted for the largest global degenerative disc disease treatment market share of 35.1% in 2022 and is expected to hold major share and rise at a CAGR of 6.2% during the forecast period. NSAIDs' effectiveness in reducing pain, inflammation, and fever, their over-the-counter availability, and their ability to address multiple symptoms simultaneously drive their widespread use for various conditions like arthritis and minor ailments, which is driving the sub-segment's growth. In addition, NSAIDs are a popular choice for self-medication.

Treatment Type: Physical Therapy Sub-segment to Flourish Immensely During the Forecast Period

The physical therapy sub-segment held the largest market share of 30.6% in 2022 and is predicted to grow at the highest CAGR of 6.5% during the forecast period. This dominant growth can be attributed to physical therapy's non-invasive nature, its proven effectiveness in reducing pain and improving mobility, and its use of therapeutic exercises and modalities like ultrasound and electrical stimulation make it a preferred treatment for degenerative disc disease. This approach appeals to both patients and healthcare providers seeking conservative management options.

Route of Administration: Oral Sub-segment to Witness Dominant Growth by 2032

The oral control sub-segment accounted for the largest global degenerative disc disease treatment market share of 65.5% in 2022 and is expected to be most dominant by growing at the highest CAGR of 6.0% during the forecast period. This is mainly because oral medications for degenerative disc disease, such as NSAIDs, muscle relaxants, and analgesics, offer convenience and ease of administration, making them preferred by patients and healthcare providers. Their availability over-the-counter or with a prescription ensures accessibility in hospitals, clinics, and pharmacies, providing flexibility in managing the condition.

End Use: Hospitals Sub-segment to Thrive Significantly During the Forecast Period

The hospitals sub-segment held the largest market share of 45.5% in 2022 and is predicted to grow at the highest CAGR of 6.2% during the forecast period. This is mainly because specialized departments in hospitals dedicated to orthopedics, neurology, or spine care, equipped with advanced diagnostic tools and treatment modalities enable comprehensive care for patients with complex spinal conditions. This infrastructure drives hospitals to become preferred destinations for specialized treatment of degenerative disc disease.

For Purchase Enquiry- https://www.alliedmarketresearch.com/purchase-enquiry/A269439 

Region: North America Market to Hold Major Share by 2032

The North America degenerative disc disease treatment market accounted for the largest share of 34.1% in 2022 and is predicted to continue to hold major share by 2032. This is mainly due to the advancements in medical technology, rising healthcare expenditure, and increased patient awareness. Besides, the increasing prevalence of degenerative disc disease (DDD) attributed to aging populations and sedentary lifestyles is another factor driving the regional market growth.

Leading Players in the Degenerative Disc Disease Treatment Market:

• Eli Lilly and Company
• Spine BioPharma
• Novartis AG
• FibroGenesis
• Ferring B.V.
• Pfizer Inc.
• AstraZeneca Plc
• Medtronic plc
• DiscGenics, Inc.
• Braun Melsungen AG

The report provides a detailed analysis of the key players of the global degenerative disc disease treatment market. These players are employing various strategies including launching new products, entering collaborations, expanding operations, forming joint ventures, and signing agreements, all aimed at boosting their market share and securing their competitive position across different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact

David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int'l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com  
Follow Us on: LinkedIn Twitter

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/degenerative-disc-disease-treatment-market-to-reach-46-2-billion-globally-by-2032-at-5-5-cagr-allied-market-research-302154006.html